<!doctype html><html lang=en><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge,chrome=1"><title>Pharmacotherapy - PSYC1022 Musings</title><meta name=renderer content="webkit"><meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1"><meta http-equiv=cache-control content="no-transform"><meta http-equiv=cache-control content="no-siteapp"><meta name=theme-color content="#f8f5ec"><meta name=msapplication-navbutton-color content="#f8f5ec"><meta name=apple-mobile-web-app-capable content="yes"><meta name=apple-mobile-web-app-status-bar-style content="#f8f5ec"><meta name=author content="z5206677"><meta name=description content="Pharmacotherapy  Modify the biological processes that underpin the motivation to take drugs."><meta name=keywords content="featherbear,PSYC1022,UNSW"><meta name=generator content="Hugo 0.68.3 with theme even"><link rel=canonical href=../../post/pharmacotherapy/><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../manifest.json><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><link href=../../sass/main.min.651e6917abb0239242daa570c2bec9867267bbcd83646da5a850afe573347b44.css rel=stylesheet><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/@fancyapps/fancybox@3.1.20/dist/jquery.fancybox.min.css integrity="sha256-7TyXnr2YU040zfSP+rEcz29ggW4j56/ujTPwjMzyqFY=" crossorigin=anonymous><link rel=stylesheet href=../../css/typedjs.shortcode.css><link rel=stylesheet href=../../css/fixDetails.css><link rel=stylesheet href=../../css/fancyBox.css><meta property="og:title" content="Pharmacotherapy"><meta property="og:description" content="Pharmacotherapy  Modify the biological processes that underpin the motivation to take drugs."><meta property="og:type" content="article"><meta property="og:url" content="/post/pharmacotherapy/"><meta property="article:published_time" content="2021-02-04T06:16:26+00:00"><meta property="article:modified_time" content="2021-02-05T10:52:06+00:00"><meta itemprop=name content="Pharmacotherapy"><meta itemprop=description content="Pharmacotherapy  Modify the biological processes that underpin the motivation to take drugs."><meta itemprop=datePublished content="2021-02-04T06:16:26+00:00"><meta itemprop=dateModified content="2021-02-05T10:52:06+00:00"><meta itemprop=wordCount content="746"><meta itemprop=keywords content><meta name=twitter:card content="summary"><meta name=twitter:title content="Pharmacotherapy"><meta name=twitter:description content="Pharmacotherapy  Modify the biological processes that underpin the motivation to take drugs."><!--[if lte IE 9]><script src=https://cdnjs.cloudflare.com/ajax/libs/classlist/1.1.20170427/classList.min.js></script><![endif]--><!--[if lt IE 9]><script src=https://cdn.jsdelivr.net/npm/html5shiv@3.7.3/dist/html5shiv.min.js></script><script src=https://cdn.jsdelivr.net/npm/respond.js@1.4.2/dest/respond.min.js></script><![endif]--></head><body><div id=mobile-navbar class=mobile-navbar><div class=mobile-header-logo><a href=../../ class=logo>PSYC1022 Musings</a></div><div class=mobile-navbar-icon><span></span><span></span><span></span></div></div><nav id=mobile-menu class="mobile-menu slideout-menu"><ul class=mobile-menu-list><a href=../../><li class=mobile-menu-item>Home</li></a><a href=https://github.com/featherbear/UNSW-PSYC1022><li class=mobile-menu-item>GitHub</li></a><a href=../../categories/><li class=mobile-menu-item>Categories</li></a></ul></nav><div class=container id=mobile-panel><header id=header class=header><div class=logo-wrapper><a href=../../ class=logo>PSYC1022 Musings</a></div><nav class=site-navbar><ul id=menu class=menu><li class=menu-item><a class=menu-item-link href=../../>Home</a></li><li class=menu-item><a class=menu-item-link href=https://github.com/featherbear/UNSW-PSYC1022>GitHub</a></li><li class=menu-item><a class=menu-item-link href=../../categories/>Categories</a></li></ul></nav></header><main id=main class=main><div class=content-wrapper><div id=content class=content><article class=post><header class=post-header><h1 class=post-title>Pharmacotherapy</h1><div class=post-meta><span class=post-time>2021-02-04</span><div class=post-category><a href=../../categories/pharmacotherapy/>Pharmacotherapy</a></div></div></header><div class=post-toc id=post-toc><h2 class=post-toc-title>Contents</h2><div class="post-toc-content always-active"><nav id=TableOfContents><ul><li><a href=#pharmacotherapy>Pharmacotherapy</a><ul><li><a href=#naltrexone>Naltrexone</a></li><li><a href=#disulfiram-antabuse>Disulfiram (Antabuse)</a></li><li><a href=#nicotine-replacements>Nicotine Replacements</a></li><li><a href=#bupropion-zyban>Bupropion (Zyban)</a></li><li><a href=#varenicline-champix>Varenicline (Champix)</a></li></ul></li><li><a href=#treatments>Treatments</a></li><li><a href=#cognitive-enhancers>Cognitive Enhancers</a></li></ul></nav></div></div><div class=post-content><h1 id=pharmacotherapy>Pharmacotherapy</h1><blockquote><p>Modify the biological processes that underpin the motivation to take drugs.</p></blockquote><p>e.g. some block the neural substrates of reward - i.e block the euphoric effects</p><p>Agonist - activate receptors to increase their function (by excitation or inhibition)<br>Antagonist - block the action of the neurotransmitter.</p><p>Full agonist - activates a receptor to its maximum<br>Partial agonist - function as a 'competitive antagonist' by occupying receptors<br>Indirect agonist - enhance the function of neurotransmitters without activating the receptors for the transmitter (i.e. blocking transports, inducing release inhibiting metabolism)</p><p><img src=../../uploads/snipaste_2021-02-04_17-40-26.png alt></p><hr><p>Alcohol increases NT GABA, decreases the NT glutamate -> reduce activity across the nervous system. Chronic occupancy can result in downregulation or desensitisation where withdrawal from alcohol will result in a lack - dangerous!</p><p>Acamprosate - A GABA agonist and glutamate NMDA antagonist - that can oppose the neural effects that may have happened following alcohol withdrawal</p><blockquote><p>Boismare et al (1984) gave rats acamprosate, and found that they reduced alcohol consumption</p></blockquote><p><img src=../../uploads/snipaste_2021-02-04_17-44-06.png alt></p><ul><li>Filled circles - placebo control group</li><li>Triangles - different dosages</li></ul><p>Unclear of the whether acamprosate reversed withdrawal or competed with direct rewarding effects of alcohol.</p><blockquote><p>Mason and Heyser (2010)<br><img src=../../uploads/snipaste_2021-02-04_17-46-30.png alt><br>Showed that there is a significant effect of the use of acamprosate</p></blockquote><p>Increased abstinence rates by about 10-20% over 80 days following the quit date</p><h2 id=naltrexone>Naltrexone</h2><p>An antagonist of opioid receptors, blocking the function of endogenous endorphins.</p><p>First studied for alcohol dependence in the 1970s, following discovery of the role of opiate receptors in opiate dependence.</p><p>Naltrexone + Acamprosate = Additive treatment effects, broader protection from relapse</p><blockquote><p>Maisel et al 2013 found that acamprosate increased the number of abstitenent days more than naltrexone, but naltrexone reduced craving and heavy drinking sessions.<br>Acamprosate makes the effects of withdrawal less bad<br>Naltrexone blocks the euphoric effects of alcohol, reducing craving and heavy use</p></blockquote><h2 id=disulfiram-antabuse>Disulfiram (Antabuse)</h2><p>Treatment for alcoholism</p><p>Blocks acetaldehyde dehydrogenase (a liver enzyme that breaks down alcohol), increases the sensitivity to alcohol consumption - causing them to consume less of the alcohol to feel the same effect.</p><p><strong>Dangerous for those who take it unknowingly</strong></p><p>Hard to make clients comply and continually take it.<br>- Attempted depot treatment (slow down the release so that it can be taken less frequently)</p><p><strong>Now rarely used as treatment (Heilig & Egli 2006)</strong></p><h3 id=methadone>Methadone</h3><p>For treating heroin and opiate dependence.</p><p>Has a higher oral bioavailability and longer half-life, making it useful for maintenance therapy.</p><p>Needs to be closely monitored by professionals - need regular visits to a clinic</p><p><img src=../../uploads/snipaste_2021-02-04_17-57-17.png alt></p><h4 id=suboxone>Suboxone</h4><blockquote><p>Developed so that opiate addicts <strong>do not need</strong> to regularly visit a clinic.</p></blockquote><p>Combination of buprenorphine (partial opiod receptor agonist with a good oral bioavailability) and naloxone (opiod receptor antagonist).</p><p>As naloxone has a poor oral bioavailability, the administration of suboxone is more rewarding as a result of the buprenorphine.</p><p>If injected, the naloxone counters the opioid agonist effects, making the injection unrewarding.</p><p>This causes suboxone to be taken orally more pleasurably than via injections.</p><h2 id=nicotine-replacements>Nicotine Replacements</h2><blockquote><p>In 1967, Dr Claes Lundgren suggested nicotine as a substitute for tobacco, having seen sailors switch from smoking to chewing tobacco</p></blockquote><p>Ove Ferno designed nicotine gum as a means to orally administer nicotine with delayed absorption.</p><p><img src=../../uploads/snipaste_2021-02-04_18-03-58.png alt></p><p>Abstinence increased a lot, however it did not improve absolute quit rates.<br>However, effective at reducing the frequency of smoking (Wang et al 2008)</p><h2 id=bupropion-zyban>Bupropion (Zyban)</h2><p>Bupropion is a dopamine, noradrenaline indirect agonist // reuptake inhibitor, and antagonist for nicotine acetylcholine receptors. Blocks the rewarding effects of nicotine, rather than by reversing withdrawal induced depression - which may improve abstinence rates</p><blockquote><p>Tobacco withdrawal syndrome is associated with a marked increase in depression, which furthers the inability to quit smoking</p></blockquote><p>Anti-depressent agents may protect against relapse by decreasing depression tendency.</p><blockquote><p>Hurt et al (1997) found that the anti-depresant bupropion produced superior quit rates, marketed as a smoking cessation agent under the name Zyban.</p></blockquote><h2 id=varenicline-champix>Varenicline (Champix)</h2><p>Acetylcholine partial agonist - weak nicotine replacement agent to make acetylcholine neurons reverse withdrawal related hypofunction, and blocks the rewarding effects of smoking by competing with nicotine.</p><p>Demonstrated to be slightly more effective as a smoking cessation agent than NRT or bupriopion. Though absolute quit rates still remain low</p><p><img src=../../uploads/snipaste_2021-02-04_18-12-11.png alt></p><h3 id=gabapentin>Gabapentin</h3><p>THC activates CB1 receptors to inhibit other cells, increasing over brain inhibition. Following cannabis withdrawal, the brain over-excitates.</p><p>Gabapentin seems to help to reduce both cannabis use and withdrawal</p><h1 id=treatments>Treatments</h1><p><img src=../../uploads/snipaste_2021-02-04_18-13-06.png alt><br><img src=../../uploads/snipaste_2021-02-04_18-14-02.png alt></p><p>Currently no effective medication against cocaine, amphetamine or cannabis addiction.</p><h1 id=cognitive-enhancers>Cognitive Enhancers</h1><p>Drugs that improve performance on some metric</p><p><img src=../../uploads/snipaste_2021-02-04_18-23-09.png alt></p><p>None of them have compelling efficacy to treat addiction</p></div><footer class=post-footer><nav class=post-nav><a class=prev href=../../post/quiz/pharmacotherapy/><i class="iconfont icon-left"></i><span class="prev-text nav-default">Pharmacotherapy</span>
<span class="prev-text nav-mobile">Prev</span></a>
<a class=next href=../../post/quiz/behavioural-interventions/><span class="next-text nav-default">Quiz: Behavioural Interventions</span>
<span class="next-text nav-mobile">Next</span>
<i class="iconfont icon-right"></i></a></nav></footer></article></div></div></main><footer id=footer class=footer><div class=social-links><a href=mailto:z5206677@student.unsw.edu.au class="iconfont icon-email" title=email></a><a href=https://www.linkedin.com/in/andrewjinmengwong/ class="iconfont icon-linkedin" title=linkedin></a><a href=https://github.com/featherbear class="iconfont icon-github" title=github></a><a href=https://www.instagram.com/_andrewjwong/ class="iconfont icon-instagram" title=instagram></a><a href=../../index.xml type=application/rss+xml class="iconfont icon-rss" title=rss></a></div><div class=copyright><span class=power-by>Powered by <a class=hexo-link href=https://gohugo.io>Hugo</a></span>
<span class=division>|</span>
<span class=theme-info>Theme -
<a class=theme-link href=https://github.com/olOwOlo/hugo-theme-even>Even</a></span>
<span class=copyright-year>&copy;
2021
<span class=heart><i class="iconfont icon-heart"></i></span><span class=author>Andrew Wong (z5206677)</span></span></div></footer><div class=back-to-top id=back-to-top><i class="iconfont icon-up"></i></div></div><script src=https://cdn.jsdelivr.net/npm/jquery@3.2.1/dist/jquery.min.js integrity="sha256-hwg4gsxgFZhOsEEamdOYGBf13FyQuiTwlAQgxVSNgt4=" crossorigin=anonymous></script><script src=https://cdn.jsdelivr.net/npm/slideout@1.0.1/dist/slideout.min.js integrity="sha256-t+zJ/g8/KXIJMjSVQdnibt4dlaDxc9zXr/9oNPeWqdg=" crossorigin=anonymous></script><script src=https://cdn.jsdelivr.net/npm/@fancyapps/fancybox@3.1.20/dist/jquery.fancybox.min.js integrity="sha256-XVLffZaxoWfGUEbdzuLi7pwaUJv1cecsQJQqGLe7axY=" crossorigin=anonymous></script><script type=text/javascript src=../../js/main.min.d7b7ada643c9c1a983026e177f141f7363b4640d619caf01d8831a6718cd44ea.js></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-107434487-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script src=../../js/typed.js@2.0.9></script><script src=../../js/typedjs.shortcode.js></script></body></html>